Polymeric Anti‐Antibiotic Microparticles to Prevent Antibiotic Resistance Evolution (Small 21/2025) | Zendy

Koshani Roya | Zendy; Yeh ShangLin | Zendy; He Zeming | Zendy; Narasimhalu Naveen | Zendy; vom Steeg Landon G. | Zendy; Sim Derek G. | Zendy; Woods Robert J. | Zendy; Read Andrew F. | Zendy; Sheikhi Amir | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Polymeric Anti‐Antibiotic Microparticles to Prevent Antibiotic Resistance Evolution (Small 21/2025)

Author(s) -

Koshani Roya,

Yeh ShangLin,

He Zeming,

Narasimhalu Naveen,

vom Steeg Landon G.,

Sim Derek G.,

Woods Robert J.,

Read Andrew F.,

Sheikhi Amir

Publication year - 2025

Publication title -

small

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.785

H-Index - 236

eISSN - 1613-6829

pISSN - 1613-6810

DOI - 10.1002/smll.202570165

Antibiotic Resistance In article number 2407549, Amir Sheikhi and co‐workers report sevelamer (SEV), a Food and Drug Administration (FDA)‐approved polymeric microparticle, as an adjuvant therapy to combat antimicrobial resistance. SEV captures off‐target vancomycin and daptomycin in the gastrointestinal tract, preventing resistance enrichment in Enterococcus faecium . SEV therapy protects the last‐resort antibiotics, which may address the global antimicrobial resistance crisis. Image created with BioRender.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Empowering knowledge with every search